The domestic sales of Bayer HealthCare's birth control products grew 13 percent last year, driven by the strength of Myvlar, Minivlar and Postinor-1. But Bayer HealthCare is not stagnating.
Approved by the Korea Food and Drug Administration this month, Yasmin, a new contraceptive pill, which is pitched to clear the skin and improve premenstrual symptoms, will become the emerging oral contrac...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.